Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Wharton et al
Pfizer Secures Global Rights to Fosun Pharmas Oral GLP-1 Program Chinas Fosun Pharma has signed a major collaboration and licensing deal with Pfizer, marking a significant move in the competitive metabolic-disease market
Contiene soja
Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, stated, Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH. He noted that this approval complements the proven weight loss, cardiovascular benefits, and broader evidence linked to semaglutide
US$ 22.18
US$ 25.57
US$ 20.56
US$ 26.64
US$ 23.27
US$ 20.17
